McKesson Corporation (MCK)
NYSE:MCK
Want to see MCK full AI Analyst Report?
MCK Stock Chart & Stats
$760.57
$1.72(0.29%)
At close: 4:00 PM EST
$760.57
$1.72(0.29%)
Day’s Range― - ―
52-Week Range$637.00 - $999.00
Previous CloseN/A
Volume137.88K
Average Volume (3M)1.28M
Market Cap
$88.56B
Enterprise Value$93.88B
Total Cash (Recent Filing)$3.98B
Total Debt (Recent Filing)$8.61B
Price to Earnings (P/E)18.9
Beta0.22
Next Earnings
Aug 05, 2026EPS Estimate
9.68Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)38.64
Shares Outstanding120,204,050
10 Day Avg. Volume1,396,594
30 Day Avg. Volume1,276,982
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)-49.24
Price to Sales (P/S)0.27
P/FCF Ratio18.70
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue0.23
Enterprise Value/Gross Profit6.45
Enterprise Value/Ebitda13.04
Forecast
1Y Price Target
$946.91Price Target Upside24.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)44.25
Revenue Forecast (FY)$432.87B
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Earnings RecoveryMcKesson has materially expanded top-line scale and converted that into a meaningful earnings rebound from prior losses. Persistent revenue growth and EPS recovery reflect durable demand, stronger execution across segments, and greater capacity to fund investments and shareholder returns over the medium term.
Robust Cash Generation And Shareholder ReturnsConsistent, sizable operating and free cash flow supports ongoing buybacks and dividends while funding strategic initiatives. Strong FCF capacity provides financial flexibility to execute the Medical‑Surgical separation, fund acquisitions and automation investments without over-relying on equity issuance.
Scale And Specialty Momentum (oncology & Biopharma)Rapid oncology and biopharma expansion builds higher-margin, sticky service relationships and diversifies revenue beyond commodity drug distribution. Growing provider network and acquisitions increase scale advantages, recurring service fees, and long-term cross-sell opportunities across pharmacy and specialty channels.
Bears Say
Structurally Thin MarginsMcKesson operates a high-volume, low-margin distribution model where small adverse pricing, mix or reimbursement moves materially compress profits. Thin structural margins leave limited buffer for cost shocks, making sustained margin expansion and earnings resilience contingent on execution and favorable product mix.
Balance-sheet Legacy And Leverage RelianceAlthough equity is positive again, the multi-year history of negative equity and meaningful debt (debt-to-equity ~1.25x) raise financing and perception risk. Leverage constrains flexibility during separation, increases sensitivity to covenant tests, and can magnify volatility in returns if cash flow weakens.
Cash-flow Volatility And Separation Interest HeadwindsManagement expects a notable FCF step-down and higher interest costs tied to Medical‑Surgical separation financing. Falling and volatile free cash flow plus rising below‑the‑line interest reduces runway for capital allocation, increases reliance on credit facilities, and raises execution risk during the separation process.
McKesson News
MCK FAQ
What was McKesson Corporation’s price range in the past 12 months?
McKesson Corporation lowest stock price was $637.00 and its highest was $999.00 in the past 12 months.
What is McKesson Corporation’s market cap?
McKesson Corporation’s market cap is $88.56B.
When is McKesson Corporation’s upcoming earnings report date?
McKesson Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 63 days.
How were McKesson Corporation’s earnings last quarter?
McKesson Corporation released its earnings results on May 07, 2026. The company reported $11.69 earnings per share for the quarter, beating the consensus estimate of $11.565 by $0.125.
Is McKesson Corporation overvalued?
According to Wall Street analysts McKesson Corporation’s price is currently Undervalued.
Does McKesson Corporation pay dividends?
McKesson Corporation pays a Quarterly dividend of $0.82 which represents an annual dividend yield of 0.37%. See more information on McKesson Corporation dividends here
What is McKesson Corporation’s EPS estimate?
McKesson Corporation’s EPS estimate is 9.68.
How many shares outstanding does McKesson Corporation have?
McKesson Corporation has 120,204,050 shares outstanding.
What happened to McKesson Corporation’s price movement after its last earnings report?
McKesson Corporation reported an EPS of $11.69 in its last earnings report, beating expectations of $11.565. Following the earnings report the stock price went down -2.474%.
Which hedge fund is a major shareholder of McKesson Corporation?
Currently, no hedge funds are holding shares in MCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
McKesson Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$946.91 (24.50% Upside)
$946.91 (24.50% Upside)
Blogger Sentiment
Bullish
MCK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 323.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.49%
12-Months-Change
Fundamentals
Return on Equity
-265.44%
Trailing 12-Months
Asset Growth
9.56%
Trailing 12-Months
Company Description
McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
MCK Company Deck
MCK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
McKesson reported a strong fiscal 2026 with double-digit revenue, operating profit and EPS growth, robust cash generation and material progress on strategic initiatives (oncology expansion, biopharma scale, supply chain modernization, and Medical‑Surgical separation). The company is returning significant capital to shareholders and reaffirmed long‑term targets. Offsetting risks include branded pricing pressure (IRA effects), sequential GLP‑1 volatility, ongoing integration and corporate expense investments, and near‑term cash flow/interest impacts related to separation financing. On balance the positives (broad-based growth, margin expansion, cash returns, strategic progress) outweigh the negatives, though the business faces near-term variability and execution/approval risks tied to the Medical‑Surgical separation.View all MCK earnings summariesMCK Revenue Breakdown
83.45% North American Pharmaceutical
12.00% Oncology & Multispecialty
1.44% Prescription Technology Solutions
2.85% Medical-Surgical Solutions
0.26% Other
MCK Stock 12 Month Forecast
Average Price Target
$946.91
▲(24.50% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
23.57% Mutual Funds
14.58% Other Institutional Investors
39.32% Public Companies and Individual Investors